跳至主要内容
临床试验/NCT01139320
NCT01139320已完成不适用

Pharmacogenetics of Mylotarg

Children's Oncology Group0 个研究点目标入组 300 人开始时间: 2009年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
300
主要终点
Association between coding polymorphisms in CD33 with clinical response to gemtuzumab ozogamicin

研究概览

简要总结

RATIONALE: Studying samples of DNA from patients receiving gemtuzumab ozogamicin may help doctors learn more about the effects of gemtuzumab ozogamicin on cells. It may also help doctors understand how well patients respond to treatment.

PURPOSE: This research study is studying biomarkers in DNA samples from younger patients with newly diagnosed with acute myeloid leukemia receiving gemtuzumab ozogamicin.

详细描述

OBJECTIVES:

  • To analyze candidate-coding polymorphisms in CD33 of DNA samples from children with newly diagnosed acute myeloid leukemia treated with gemtuzumab ozogamicin on COG-AAML03P1.
  • To determine the association between these polymorphisms and clinical response of patients treated with this regimen.

OUTLINE: Archived DNA samples are analyzed for candidate polymorphisms in CD33 by PCR-based sequencing.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
— 至 21 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Association between coding polymorphisms in CD33 with clinical response to gemtuzumab ozogamicin

次要结局

未报告次要终点

研究者

申办方类型
Network
责任方
Sponsor

相似试验

Biomarkers in DNA Samples From Younger Patients With... | 临床试验